Use of irradiated stem cells for the treatment of cancer
This invention is based on the fact that the mesenchymal cells activated with radiation are a source of cytokines, and their administration together with the radiotherapy and PARP inhibitors cause an increase in the levels of cytokines freed in the heart of the tumour, which means an increase in the effectiveness of radiotherapy via the promotion of cell death.
After selecting and isolating the adult stem cells (more specifically mesenchymal stem cells obtained from human umbilical cord), they can be genetically modified to change the expression of genes that are important for their basic properties, or to code proteins of interest.
The radiation of the adult stem cells is carried out via standard techniques and megavoltage equipment so that, once the desired composition of cells is obtained, they can be incorporated into a medium that is compatible with them and that permits their transport in a diluent, coadjuvant or duly appropriate vessel for their use in animals, and more specifically in humans.
Licence agreement for operation and/or collaboration.
Sectors of application: Medicine, pharmacy, drugs.
Stage of development: Patent in process.
Priority date: 23/12/2014.
Owner: University of Granada, Andalusia Health Service and CSIC.